Mafalda A. Oliveira

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 133 publications

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: April 24, 2026

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

Journal: Breast (Edinburgh, Scotland)

Published: April 08, 2026

Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.

Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 23, 2026

Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer.

Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer.

Journal: NPJ breast cancer

Published: February 13, 2026

Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 27, 2026

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Journal: NPJ precision oncology

Published: January 23, 2026

Evolving landscape of targeted therapies in early phase clinical trials.

Evolving landscape of targeted therapies in early phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 04, 2026

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Journal: ESMO open

Published: December 17, 2025

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 08, 2025

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.

Journal: ESMO open

Published: October 27, 2025

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

Journal: The New England journal of medicine

Published: October 22, 2025

Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis.

Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis.

Journal: Cancer treatment reviews

Published: October 05, 2025

Showing 1-12 of 133

Last Updated: 09/26/2026